Penmaen Software - QBR
Documentfinal Penmaen Software · QBR deck · final · 21 Dec 2025
A BG-Demo quarterly review deck for the Growth tier, prepared by Marcus Bell on 21 Dec 2025. It states contracted annual recurring revenue of £48k, 40 licensed users and a term ending 24 Jul 2026, and finds usage steady but well below the licence.
What it says
What this says
As at Fri 9 Oct 2026A BG-Demo quarterly review deck for the Growth tier, prepared by Marcus Bell on 21 Dec 2025. It states contracted annual recurring revenue of £48k, 40 licensed users and a term ending 24 Jul 2026, and finds usage steady but well below the licence.
What it is: a customer-facing QBR deck by Marcus Bell, Customer Success Manager, with Tom Ashdown named as account owner. It is a review, not a contract, and it states no availability or P1 response figure.
States: "Contracted annual recurring revenue of £48k" and "Current term ends 24 Jul 2026". Active users are "just under nine across a month, well below the licensed number".
Risk: the deck itself says most of the licence is unused and that value is not yet measured, "the first thing to look at when the value of the subscription is discussed". It also notes the business has no return measure it would quote.
Not settled: the deck gives no price change at renewal and names no customer attendee. It does not say whether the £48k matches the executed order form, which would decide the contracted price.
As found in this document
As at Fri 9 Oct 2026- Date end24 Jul 2026Source: the AI read of this record
- Date renewal24 Jul 2026Source: the AI read of this record
Body
Penmaen Software - QBR
Prepared by: Marcus Bell, Customer Success Manager Account owner: Tom Ashdown Date: 21 Dec 2025 Tier: Growth
1. Purpose of this review
- Look at how Penmaen Software is using the brain since joining on 25 Jul 2024.
- Agree what the team wants to get from it in the coming quarter.
- Make sure nothing is a surprise ahead of the renewal on 24 Jul 2026.
2. Your contract in brief
- Growth tier, with licensed users numbering 40.
- Contracted annual recurring revenue of £48k.
- Current term ends 24 Jul 2026.
- Invoices are up to date and nothing is overdue.
3. Usage
I've pulled the numbers for the last quarter.
- Active users are averaging just under nine across a month, well below the licensed number.
- That is a small dip on the prior quarter, not a sharp fall.
- Usage is steady rather than growing. The same core group is asking most of the questions.
- Reading tickets, renewals and usage per leisure operator remains the main use.
Read the whole document (2,513 characters)
What this tells us: the people who use the brain use it regularly, but most of the licence is unused. That is headroom, and also the first thing to look at when the value of the subscription is discussed.
4. Value delivered
- Customer success can see tickets, renewals and usage per leisure operator in one place, which was the reason for buying Growth.
- The team no longer has to reconcile those views by hand before account reviews.
- We have not yet captured a measure the business itself would quote as the return. That is worth agreeing together.
5. Support and service
- No tickets were raised in the last 30 days.
- No high priority tickets are open.
- Nightly refresh has completed on schedule, so the data the team sees is current.
6. Points to discuss
- Who else at Penmaen Software could use the brain, for example colleagues in support or finance?
- Whether the dashboards builder, included in Growth, would help the team share views more widely.
- Whether the connectors in place still match the systems the team works in.
7. Next steps
| Action | Owner | By when |
|---|---|---|
| Share a short usage summary by team and by person | Marcus Bell | Within the next two weeks |
| Agree two or three questions the wider team should be asking | Marcus Bell with the Penmaen Software lead | Before the next review |
| Open the renewal conversation and confirm requirements | Tom Ashdown | Well ahead of 24 Jul 2026 |
Happy to jump on a call if anything here needs more detail.